SpaceX, OpenAI, and Anthropic carry a combined valuation of $2.8T to $3T, with SpaceX alone expected to raise $50B - $70B in ...
The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...
The IPO window has reopened, but diversity hasn’t followed suit. According to research performed by Free Float Analytics’ cofounder Damion Rallis, 88% of the 61 companies filing to go public in August ...
Ahead of the World Economic Forum‘s Annual Meeting in Davos, Switzerland, Fortune connected with Goldman Sachs’ global co-head of investment banking, Kim Posnett, for her outlook on the most urgent ...
After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?
As the global business community converges at Davos, we are seeing powerful catalysts driving M&A and capital markets activity. The foundational drivers that accelerated business activity in the ...